Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Almirall, S.A. (ALM.MC)
Barcelona, ES
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -4.90% | -10.46% | -12.87% | -5.67% | -9.35% | +7.78% | +33.33% | -20.27% | -12.28% | -22.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.4% ★ Q1'26: +1.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+358.3% ★ Q1'26: -28.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.6% ★ Q1'26: +8.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.1% Q1'26: +68.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.8% Q1'26: +35.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.6% Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.57× Q1'26: 0.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 10 EPS Ana. |
Dec 2027 10 Rev. Ana. 10 EPS Ana. |
Dec 2028 9 Rev. Ana. 9 EPS Ana. |
Dec 2029 4 Rev. Ana. 3 EPS Ana. |
Dec 2030 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
689.23M
est: 702.47M (-1.9%)
|
764.36M
est: 775.45M (-1.4%)
|
639.38M
est: 652.14M (-2.0%)
|
756.93M
est: 761.43M (-0.6%)
|
855.34M
est: 872.48M (-2.0%)
|
1.61B
est: 814.79M (+98.2%)
|
827.20M
est: 816.86M (+1.3%)
|
863.25M
est: 858.26M (+0.6%)
|
894.52M
est: 931.63M (-4.0%)
|
985.72M
est: 977.98M (+0.8%)
|
1.11B
est: 1.11B (+0.1%)
|
1.23B
1.22B – 1.24B
+11.1% YoY
|
1.36B
1.33B – 1.42B
+10.8% YoY
|
1.48B
1.48B – 1.48B
+8.6% YoY
|
1.61B
1.58B – 1.65B
+9.0% YoY
|
1.68B
1.65B – 1.72B
+4.0% YoY
|
| EBITDA |
247.30M
est: 109.32M (+126.2%)
|
213.08M
est: 120.68M (+76.6%)
|
-212.19M
est: 101.49M (-309.1%)
|
173.10M
est: 118.50M (+46.1%)
|
263.83M
est: 135.78M (+94.3%)
|
213.35M
est: 126.80M (+68.3%)
|
132.34M
est: 127.12M (+4.1%)
|
157.01M
est: 133.56M (+17.6%)
|
114.33M
est: 157.17M (-27.3%)
|
173.80M
est: 164.99M (+5.3%)
|
218.90M
est: 186.79M (+17.2%)
|
207.46M
205.26M – 209.34M
+11.1% YoY
|
229.78M
224.21M – 239.23M
+10.8% YoY
|
249.58M
248.93M – 250.23M
+8.6% YoY
|
272.10M
267.27M – 279.16M
+9.0% YoY
|
283.03M
278.00M – 290.37M
+4.0% YoY
|
| EBIT |
172.64M
est: 19.26M (+796.4%)
|
92.64M
est: 21.26M (+335.7%)
|
-321.06M
est: 17.88M (-1,895.7%)
|
80.54M
est: 20.88M (+285.8%)
|
134.40M
est: 23.92M (+461.9%)
|
90.27M
est: 22.34M (+304.1%)
|
3.89M
est: 22.40M (-82.6%)
|
36.37M
est: 23.53M (+54.6%)
|
-9.98M
est: 26.51M (-137.7%)
|
34.72M
est: 27.83M (+24.7%)
|
67.71M
est: 31.51M (+114.9%)
|
35.00M
34.62M – 35.31M
+11.1% YoY
|
38.76M
37.82M – 40.36M
+10.8% YoY
|
42.10M
41.99M – 42.21M
+8.6% YoY
|
45.90M
45.08M – 47.09M
+9.0% YoY
|
47.74M
46.90M – 48.98M
+4.0% YoY
|
| Net Income |
131.83M
est: 125.00M (+5.5%)
|
75.48M
est: 132.77M (-43.2%)
|
-303.96M
est: -32.18M (-844.4%)
|
77.67M
est: 134.52M (-42.3%)
|
105.91M
est: 181.20M (-41.5%)
|
74.28M
est: 86.97M (-14.6%)
|
-40.86M
est: 136.14M (-130.0%)
|
4.28M
est: 39.19M (-89.1%)
|
-38.47M
est: -38.47M (0.0%)
|
10.15M
est: 105.26M (-90.4%)
|
46.20M
est: 67.80M (-31.9%)
|
84.68M
72.55M – 93.88M
+24.9% YoY
|
121.66M
94.25M – 127.76M
+43.7% YoY
|
157.55M
122.48M – 168.98M
+29.5% YoY
|
194.94M
190.44M – 201.51M
+23.7% YoY
|
212.62M
207.71M – 219.79M
+9.1% YoY
|
| SGA |
67.70M
est: 54.60M (+24.0%)
|
115.51M
est: 60.27M (+91.7%)
|
105.30M
est: 50.68M (+107.7%)
|
64.00M
est: 59.18M (+8.2%)
|
44.55M
est: 67.81M (-34.3%)
|
41.18M
est: 63.33M (-35.0%)
|
39.11M
est: 63.49M (-38.4%)
|
42.43M
est: 66.70M (-36.4%)
|
119.14M
est: 89.52M (+33.1%)
|
131.57M
est: 93.98M (+40.0%)
|
130.05M
est: 106.39M (+22.2%)
|
118.16M
116.91M – 119.23M
+11.1% YoY
|
130.88M
127.70M – 136.26M
+10.8% YoY
|
142.15M
141.78M – 142.53M
+8.6% YoY
|
154.98M
152.23M – 159.00M
+9.0% YoY
|
161.21M
158.34M – 165.39M
+4.0% YoY
|
| EPS |
0.76
est: 0.59 (+28.6%)
|
0.44
est: 0.63 (-29.9%)
|
-1.76
est: -0.15 (-1,056.2%)
|
0.41
est: 0.64 (-35.6%)
|
0.61
est: 0.86 (-28.8%)
|
0.42
est: 0.41 (+2.1%)
|
-0.23
est: 0.64 (-135.7%)
|
0.02
est: 0.19 (-87.3%)
|
-0.20
est: -0.18 (-12.3%)
|
0.05
est: 0.49 (-90.2%)
|
0.22
est: 0.30 (-27.3%)
|
0.39
0.34 – 0.44
+29.2% YoY
|
0.55
0.44 – 0.59
+39.8% YoY
|
0.70
0.57 – 0.79
+28.7% YoY
|
0.91
0.89 – 0.94
+29.1% YoY
|
0.99
0.97 – 1.02
+9.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.49% | 3.51M | 0.40% |
| 2 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.17% | 574.9K | 0.23% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.17% | 574.9K | 0.23% |
| 4 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.17% | 1.23M | 0.33% |
| 5 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.16% | 1.65M | 0.58% |
| 6 | WisdomTree International SmallCap Dividend Fund DLS | 0.11% | 1.13M | 0.58% |
| 7 | Xtrackers Spain UCITS ETF 1D XESD.DE | 0.10% | 303.6K | 0.30% |
| 8 | Xtrackers Spain UCITS ETF 1C XESP.DE | 0.10% | 303.6K | 0.30% |
| 9 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.10% | 421.7K | 0.48% |
| 10 | Dimensional - International Small Cap Value ETF DISV | 0.08% | 3.78M | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carlos Gallardo Piqué | Chief Executive Officer, President, Member of Management Board & Chairman of the Board | 50.0K | male |
| Eloi Crespo Cervera | Chief Industrial Operations Officer & Member of Management Board | — | male |
| Esteve Conesa Panicot | Chief People & Culture Officer and Member of Management Board | — | male |
| Isabel Gomes | Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board | — | female |
| Jon U. Garay Alonso | Chief Financial Officer & Member of Management Board | — | male |
| Karl Ziegelbauer | Chief Scientific Officer & Member of Management Board | — | — |
| Lidia Martin Pereda | Chief Commercial Officer of Europe & International and Member of Management Board | — | female |
| Pablo Divasson del Fraile | Senior Director of Investor Relations | — | male |
| Paul Rittman | Member of Management Board and President & GM of Almirall US | — | male |
| Volker Koscielny | Chief Medical Officer & Member of Management Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALM.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
